Rubicon Research Ltd. share price
NSE: RUBICON · Healthcare
₹1,672.60 -0.27%
Closing price data, updated 17 Nov 2026. 52-week range: -11.9% from high, +174.5% above low.
Price₹1,672.60
Market cap₹27,687 Cr
P/E85.2
P/B19.55
ROE19.1%
ROCE23.6%
Debt / equity0.24
Dividend yield0.00%
EPS₹19.62
Book value₹85.56
Operating margin20.6%
Dipscan score41 / 100
Share: WhatsAppX / TwitterTelegram
Rubicon Research Ltd. shareholding pattern
As of Sep 2026: Promoters 51.25%, FIIs 9.01%, DIIs 15.72%, Government 0.00%, Public 3.89%, Others 20.13%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Promoters | 51.25% | 59.76% | 59.86% | 59.99% | 59.99% |
| FIIs | 9.01% | 7.52% | 7.54% | 7.99% | 9.37% |
| DIIs | 15.72% | 9.43% | 10.02% | 9.45% | 10.54% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 3.89% | 3.46% | 2.82% | 2.71% | 18.28% |
| Others | 20.13% | 19.84% | 19.76% | 19.86% | 1.82% |
| No. of Shareholders | 38,018 | 43,254 | 33,738 | 31,914 | 105,311 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.27% | +0.80% | +9.70% | +3.20% | +74.90% | +169.69% |
Growth
| Sales growth, 3 years | – |
| Sales growth, 5 years | – |
| Profit growth, 3 years | – |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | +39.9% |
| Latest quarter profit vs last year | +68.0% |
Strengths and weaknesses
Strengths
- Company is expected to give good quarter
- Company has delivered good profit growth of 52.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%
Weaknesses
- Stock is trading at 19.6 times its book value
- Promoter holding has decreased over last quarter: -8.51%
- Working capital days have increased from 68.8 days to 104 days
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Rubicon Research Ltd.?
Rubicon Research Ltd. (RUBICON) last closed at ₹1,672.60 (-0.27% on the day).
What is the market cap of Rubicon Research Ltd.?
About ₹27,687 Cr.
What is the P/E ratio of Rubicon Research Ltd.?
The price-to-earnings ratio is 85.2, and return on equity is 19.1%.
Figures are calculated from company results and exchange prices and are for information only.